DOP2014000055A - Derivados de pirrolopirimidina y purina - Google Patents

Derivados de pirrolopirimidina y purina

Info

Publication number
DOP2014000055A
DOP2014000055A DO2014000055A DO2014000055A DOP2014000055A DO P2014000055 A DOP2014000055 A DO P2014000055A DO 2014000055 A DO2014000055 A DO 2014000055A DO 2014000055 A DO2014000055 A DO 2014000055A DO P2014000055 A DOP2014000055 A DO P2014000055A
Authority
DO
Dominican Republic
Prior art keywords
compounds
purine derivatives
pirrolopirimidine
mammals
cell growth
Prior art date
Application number
DO2014000055A
Other languages
English (en)
Spanish (es)
Inventor
Theodore Otto Johnson Jr
John Charles Kath
Hengmiao Cheng
Kevin Kun-Chin Liu
Asako Nagata
Sajiv Krishnan Nair
Simon Paul Planken
Scott Channing Sutton
Elizabeth Ann Lunney
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47116127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2014000055(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of DOP2014000055A publication Critical patent/DOP2014000055A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DO2014000055A 2011-09-22 2014-03-21 Derivados de pirrolopirimidina y purina DOP2014000055A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161538103P 2011-09-22 2011-09-22
US201261639639P 2012-04-27 2012-04-27

Publications (1)

Publication Number Publication Date
DOP2014000055A true DOP2014000055A (es) 2014-05-15

Family

ID=47116127

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000055A DOP2014000055A (es) 2011-09-22 2014-03-21 Derivados de pirrolopirimidina y purina

Country Status (29)

Country Link
US (2) US9040547B2 (enExample)
EP (1) EP2758402B9 (enExample)
JP (1) JP5914667B2 (enExample)
KR (1) KR20140059246A (enExample)
CN (1) CN103814030A (enExample)
AP (1) AP2014007475A0 (enExample)
AR (1) AR088760A1 (enExample)
AU (1) AU2012311184A1 (enExample)
BR (1) BR112014006840A2 (enExample)
CA (1) CA2847540C (enExample)
CL (2) CL2014000566A1 (enExample)
CO (1) CO6910196A2 (enExample)
CR (1) CR20140132A (enExample)
DO (1) DOP2014000055A (enExample)
EA (1) EA201490673A1 (enExample)
ES (1) ES2575710T3 (enExample)
IL (1) IL231592A0 (enExample)
MA (1) MA35451B1 (enExample)
MD (1) MD20140023A2 (enExample)
MX (1) MX2014003501A (enExample)
NI (1) NI201400023A (enExample)
PE (1) PE20141228A1 (enExample)
PH (1) PH12014500638A1 (enExample)
SG (1) SG2014014450A (enExample)
TN (1) TN2014000115A1 (enExample)
TW (1) TWI492946B (enExample)
UA (1) UA110259C2 (enExample)
UY (1) UY34342A (enExample)
WO (1) WO2013042006A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101860057B1 (ko) 2008-05-21 2018-05-21 어리어드 파마슈티칼스, 인코포레이티드 키나아제 억제제로서 포스포러스 유도체
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
CN105061438B (zh) * 2010-06-23 2017-07-04 韩美科学株式会社 用于抑制酪氨酸激酶活性的稠合嘧啶衍生物
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
JP2014532060A (ja) * 2011-10-03 2014-12-04 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 癌を治療するためのピロロピリミジン化合物
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
KR20150018789A (ko) 2012-05-22 2015-02-24 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 암의 치료를 위한 피리미딘 화합물
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US9771330B2 (en) 2012-11-27 2017-09-26 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
JP2016505041A (ja) * 2013-01-16 2016-02-18 シグナル ファーマシューティカルズ，エルエルシー 置換型ピロロピリミジン化合物、その組成物、およびこれらを用いた治療方法
RU2015137596A (ru) * 2013-03-14 2017-04-17 Пфайзер Инк. Комбинация ингибитора EGFR T790М и ингибитора EGFR для лечения немелкоклеточного рака легкого
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
KR101657616B1 (ko) * 2013-05-24 2016-09-19 주식회사유한양행 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법
US9840517B2 (en) * 2013-09-18 2017-12-12 Beijing Hanmi Pharmaceutical Co., Ltd. Compound inhibiting activities of BTK and/or JAK3 kinases
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
UA115388C2 (uk) * 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015113451A1 (en) 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds
AU2015210593A1 (en) * 2014-01-29 2016-07-07 Glaxosmithkline Intellectual Property Development Limited Compounds
CN106458914B (zh) * 2014-03-28 2020-01-14 常州捷凯医药科技有限公司 作为axl抑制剂的杂环化合物
US9603850B2 (en) 2014-04-11 2017-03-28 The University Of North Carolina At Chapel Hill MerTK-specific pyrazolopyrimidine compounds
JP6427599B2 (ja) * 2014-05-19 2018-11-21 チャンスー ヘンルイ メディシン カンパニー，リミテッド チロシンキナーゼ阻害剤としての置換エチニルヘテロ二環式化合物
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EP3169686A4 (en) * 2014-07-14 2018-01-24 Signal Pharmaceuticals, LLC Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
CN105524068B (zh) 2014-09-30 2017-11-24 上海海雁医药科技有限公司 氮杂双环衍生物、其制法与医药上的用途
CN111170998B (zh) * 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
WO2016105528A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
HK1244278B (zh) 2015-03-20 2020-04-17 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐及其制备方法
CA2978518C (en) * 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
CN112932416A (zh) 2015-06-04 2021-06-11 松下知识产权经营株式会社 生物体信息检测装置及生物体信息检测方法
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
PL3379952T3 (pl) * 2015-11-25 2024-03-18 R. J. Reynolds Tobacco Company Kompleksy soli, kokryształów i kokryształów soli nikotyny
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
IL299415B2 (en) 2016-06-16 2025-09-01 Denali Therapeutics Inc Pyrimidine-2-ylamino-1H-pyrazoles as LRRK2 inhibitors for use in the treatment of neurodegenerative disorders
CN114795151A (zh) 2016-06-30 2022-07-29 松下知识产权经营株式会社 方法及系统
KR20180097162A (ko) 2017-02-22 2018-08-30 국립암센터 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
KR102398659B1 (ko) * 2017-03-17 2022-05-16 주식회사 대웅제약 카이네이즈 저해제로서의 피롤로트리아진 유도체
WO2019075386A1 (en) 2017-10-13 2019-04-18 The Regents Of The University Of California MODULATORS OF MTORC1
EA202091372A1 (ru) 2017-12-05 2020-10-05 Оскотек Инк. Производное пирроло(пиразоло)пиримидина в качестве ингибитора lrrk2
KR102577241B1 (ko) * 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
KR102577242B1 (ko) * 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
HUE059580T2 (hu) * 2017-12-28 2022-11-28 Daewoong Pharmaceutical Co Ltd Kináz inhibitor oxi-fluorpiperidin származékok
CN112367991A (zh) 2018-06-25 2021-02-12 达纳-法伯癌症研究所股份有限公司 Taire家族激酶抑制剂及其用途
KR102377007B1 (ko) * 2018-09-20 2022-03-22 한미약품 주식회사 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 융합 피리미딘 골격 설폰아마이드 유도체
EP3842435A4 (en) * 2018-09-20 2022-05-11 Hanmi Pharm. Co., Ltd. NEW SULFONAMIDE DERIVATIVE PRESENTING A FUSED PYRIMIDINE SKELETON, HAVING AN INHIBITOR EFFECT OF EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION
WO2020140098A1 (en) 2018-12-28 2020-07-02 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
WO2020205867A1 (en) 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Compounds targeting prmt5
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
WO2021147952A1 (zh) * 2020-01-21 2021-07-29 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN115244055B (zh) * 2020-01-21 2024-09-03 江苏先声药业有限公司 嘧啶并五元环类衍生物及其应用
TW202214643A (zh) * 2020-09-22 2022-04-16 大陸商江蘇先聲藥業有限公司 嘧啶并吡咯類化合物
CN114315838B (zh) * 2020-09-30 2024-09-03 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN114907357A (zh) * 2021-02-07 2022-08-16 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2023041071A1 (zh) * 2021-09-18 2023-03-23 山东新时代药业有限公司 一种egfr抑制剂及其制备方法和用途

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
DK0584222T3 (da) 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
EP0821671B1 (en) 1995-04-20 2000-12-27 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-anilinochinazolin derivate
WO1998002434A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
JP2000515136A (ja) 1996-07-13 2000-11-14 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての二環式ヘテロ芳香族化合物
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ES2175415T3 (es) 1996-07-18 2002-11-16 Pfizer Inhibidores de metaloproteasas matriciales basados en fosfinato.
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
IL128189A0 (en) 1996-08-23 1999-11-30 Pfizer Arylsulfonylamino hydroxamic acid derivatives
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
TR199901849T2 (xx) 1997-02-03 2000-02-21 Pfizer Products Inc. Arils�lfonilamino hidroksamik asit t�revleri.
AU5493598A (en) 1997-02-07 1998-08-26 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
CA2280151C (en) 1997-02-11 2005-12-13 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
ATE292623T1 (de) 1997-05-07 2005-04-15 Sugen Inc 2-indolinonderivate als modulatoren der proteinkinase-ativität
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
ATE368665T1 (de) 1997-08-22 2007-08-15 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
JP2001518470A (ja) 1997-09-26 2001-10-16 メルク エンド カムパニー インコーポレーテッド 新規な血管形成阻害剤
CA2309690A1 (en) 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
TR200003514T2 (tr) 1998-05-29 2002-05-21 Sugen Inc. Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
IL144675A0 (en) 1999-02-01 2002-05-23 Cv Therapeutics Inc PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-α
NZ522568A (en) 2000-06-22 2004-12-24 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cell growth
WO2002022604A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2432131C (en) 2000-12-21 2008-07-08 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
GB0101686D0 (en) * 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
US20080221060A1 (en) 2004-03-05 2008-09-11 Martyn Pritchard Therapeutic Compounds
GB0407723D0 (en) 2004-04-05 2004-05-12 Novartis Ag Organic compounds
AU2005232745A1 (en) 2004-04-13 2005-10-27 Astellas Pharma Inc. Polycyclic pyrimidines as potassium ion channel modulators
AU2005270068B2 (en) 2004-07-02 2012-04-19 Exelixis, Inc. C-Met modulators and method of use
GB0502573D0 (en) 2005-02-08 2005-03-16 Topotarget As Therapeutic compounds
GB0505219D0 (en) 2005-03-14 2005-04-20 Novartis Ag Organic compounds
GB0604944D0 (en) * 2006-03-11 2006-04-19 Vernalis R&D Ltd Pyrrolopyrimidine compounds
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
EA200900983A1 (ru) 2007-01-26 2010-02-26 Айрм Ллк Соединения и композиции в качестве ингибиторов киназы
UA93609C2 (en) * 2007-02-06 2011-02-25 Пфайзер Инк. 2-amino-5,6-dihydro-6h-pyrrolo[3, 4-d]pyrimidine derivatives as hsp-90 inhibitors for treating cancer
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US7705004B2 (en) 2007-08-17 2010-04-27 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
WO2010034740A1 (en) * 2008-09-23 2010-04-01 Palau Pharma, S.A. (r)-3-(n,n-dimethylamino)pyrrolidine derivatives
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
US20110245156A1 (en) 2008-12-09 2011-10-06 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
WO2010075282A1 (en) 2008-12-22 2010-07-01 University Of Washington Molecular inhibitors of the wnt/beta-catenin pathway
WO2010111406A2 (en) * 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
US20110207736A1 (en) 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
US20130137709A1 (en) 2010-05-05 2013-05-30 Nathanael S. Gray Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
EP2585464A2 (en) 2010-06-22 2013-05-01 University Of Central Florida Research Foundation, Inc. Substituted 2-(9h-purin-9-yl) acetic acid analogues as inhibitors of stat3
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
SG10201601507YA (en) 2010-11-29 2016-04-28 Galleon Pharmaceuticals Inc Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
WO2013041605A1 (en) * 2011-09-20 2013-03-28 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
US9665874B2 (en) 2012-03-13 2017-05-30 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
RU2015137596A (ru) 2013-03-14 2017-04-17 Пфайзер Инк. Комбинация ингибитора EGFR T790М и ингибитора EGFR для лечения немелкоклеточного рака легкого
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
CO6910196A2 (es) 2014-03-31
UY34342A (es) 2013-04-30
MD20140023A2 (ro) 2014-06-30
PH12014500638A1 (en) 2017-08-09
US20130079324A1 (en) 2013-03-28
KR20140059246A (ko) 2014-05-15
TN2014000115A1 (fr) 2015-07-01
EP2758402A1 (en) 2014-07-30
US9040547B2 (en) 2015-05-26
NI201400023A (es) 2014-10-01
CL2014002726A1 (es) 2015-02-13
JP5914667B2 (ja) 2016-05-11
EP2758402B9 (en) 2016-09-14
AP2014007475A0 (en) 2014-02-28
PE20141228A1 (es) 2014-10-01
MA35451B1 (fr) 2014-09-01
TW201313723A (zh) 2013-04-01
CL2014000566A1 (es) 2014-10-10
ES2575710T3 (es) 2016-06-30
TWI492946B (zh) 2015-07-21
CA2847540A1 (en) 2013-03-28
CR20140132A (es) 2014-05-16
AR088760A1 (es) 2014-07-02
JP2014526549A (ja) 2014-10-06
WO2013042006A1 (en) 2013-03-28
UA110259C2 (uk) 2015-12-10
SG2014014450A (en) 2014-09-26
BR112014006840A2 (pt) 2017-04-04
CN103814030A (zh) 2014-05-21
IL231592A0 (en) 2014-05-28
MX2014003501A (es) 2014-07-22
CA2847540C (en) 2016-05-17
ES2575710T9 (es) 2016-10-17
EP2758402B1 (en) 2016-04-27
AU2012311184A1 (en) 2014-03-06
EA201490673A1 (ru) 2014-06-30
US20150203502A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
DOP2014000055A (es) Derivados de pirrolopirimidina y purina
CR20160236A (es) Derivados de purina 2,6- sustituidos y su uso en el tratamiento de desordenes proliferativos
ECSP19011216A (es) Inhibidores de piridopyrimdinona cdk2/4/6
UY32483A (es) Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
CU20140110A7 (es) Compuestos heterocíclicos como inhibidores de mek
UY32916A (es) Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones
MX343264B (es) Ciertas amino-piridazinas, composiciones de las mismas y metodos de uso de los mismos.
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
NI201600040A (es) Derivados de quinozolina sustituidos útiles como inhibidores de integrasa del vih
CR11641A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
DOP2015000169A (es) Compuestos tetracíclicos sustituidos con heterociclo y usos de los mismos para el tratamiento de enfermedades víricas
UY31864A (es) Derivados de urea hetericíclica y métodos de uso de los mismos-332
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas
ECSP14013253A (es) Derivados de pirrolopirimidina y purina
CU20140033A7 (es) Derivados de pirrolopirimidina y purina
CU20100172A7 (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
CU20100237A7 (es) Derivados heterocíclicos de la urea y sus métodos de empleo